Studies have shown that PD-L1 and PD-L2 expression, the tumor mutational burden (TMB), tumor infiltrating lymphocytes (TILs), proinflammatory factors and gene mutations are related to the immune efficacy of NSCLC (9, 10). Here, CD274 is linked to non-small cell lung carcinoma.